EGFR and lung carcinoma: At present, irreversible ErbB family inhibitors against EGFR-TKI resistance, such as afatinib, have achieved good results in large-scale clinical trials and are expected to become part of a new generation of lung cancer targeted therapy drugs (Hoffknecht et al., 2015; Zhang et al., 2017).